Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS

Pharmacotherapy

Volumn 18, Issue 5, 1998, Pages 1087-1092

  Manfredi, Roberto ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; FLUCONAZOLE; INTRALIPID; ITRACONAZOLE; TRIACYLGLYCEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTHRALGIA; ARTICLE; BONE MARROW TOXICITY; CANDIDIASIS; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CRYPTOCOCCOSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; EMULSION; ESOPHAGITIS; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; CANDIDIASIS; CASE-CONTROL STUDIES; CRYPTOCOCCUS; DRUG CARRIERS; ESOPHAGITIS; FAT EMULSIONS, INTRAVENOUS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; NAUSEA;

EID: 0031704902     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Zeind CS, Cleveland KO, Menon M, Brown JR, Solomon DK. Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. Pharmacotherapy 1996;16:547-61.
2. Kauffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs 1997;53: 539-49.
3. Tollemar J, Ringdén O. Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drug Saf 1995;13: 207-18.
4. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(suppl2):S133-44.
5. Janknegt RM, De Marie S, Bakker-Woudenberg AJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 1992;23:279-91.
6. Schürmann D, De Matos Marques B, Grünewald T, Pohle HD, Hahn H, Ruf B. Safety and efficacy of liposomal amphotericin B in treating AlDS-associated disseminated cryptococcosis. J Infect Dis 1991;164:620-2.
7. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7:829-35.
8. Viviani MA, Rizzardini G, Tortorano AM, et al. Lipid-based amphotericin B in the treatment of cryptococcosis. Infection 1994;22:137-42.
9. Heinemann V, Kahny B, Debus A, Wachholz K, Jahn U. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant 1994;15(suppl 5):S8-9.
10. Andersen RP, Clark DA. Amphotericin B toxicity reduced by administration in fat emulsion. Ann Pharmacother 1995;29:496-500.
11. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.
12. Cleary JD. Amphotericin B formulated in a lipid emulsion. Ann Pharmacother 1996;30:409-12.
13. Sievers TM, Kubak BM, Wong-Beringer A. Safety and efficacy of Intralipid emulsions of amphotericin B. J Antimicrob Chemother 1996;38:333-47.
14. Andersen JM. Expense of amphotericin B product [letter]. Ann Pharmacother 1996;30:1342.
15. Persson U, Ragnarson Tennvall G, Andersson S, Tyden G, Wettermark B. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. PharmacoEconomics 1992;2:500-8.
16. Kirsh R, Goldstein R, Tarloff J, et al. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 1988;158: 1065-70.
17. Chavanet PY, Garry I, Charlier N, et al. Trial of glucose versus fat emulsion in preparation of amphotericin B for use in HIV-infected patients with candidiasis. Br Med J 1992;305:921-5.
18. Caillot D, Casasnovas O, Solary E, et al. Efficacy and tolerance of an amphotericin B lipid (lntralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31:161-9.
19. Vita E, Schroeder DJ. Intralipid in prophylaxis of amphotericin B nephrotoxicity. Ann Pharmacother 1994;28: 1182-3.
20. Joly V, Farinotti R, Saint Julien L, Cheron M, Carbon C, Yeni P. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob Agents Chemother 1994;38:177-83.
21. Caillot D, Reny G, Solary E, et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 1994;33:603-13.
22. Swenson CE, Bolcsak LE, Perkins WR, et al. Lipid-based formulations of amphotericin B. J Antimicrob Chemother 1995;35:709-13.
23. Thakur CP. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Trans R Soc Trop Med Hyg 1994;88:698-9.
24. Washington C, Lance M, Davis SS. Toxicity of amphotericin B emulsion formulations. J Antimicrob Chemother 1993;31: 806-8.
25. Sorkine P, Nagar H, Weinbroum A, et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med 1996;24:1311-15.
26. Lance MR, Washington C, Davis SS. Structure and toxicity of amphotericin B/triglyceride emulsion formulations. J Antimicrob Chemother 1995;36:119-28.
27. Shadkan Y, Segal E, Bor A, Gov Y, Rubin M, Lichtenberg D. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother 1997;39:655-8.
28. Pascual B, Ayestaran A, Montoro JB, et al. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 1995;29:1197-201.
29. Ayestaran A, Lopez RM, Montoro JB, et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob Agents Chemother 1996;40:609-12.
30. Gales MA, Gales BJ, Alford KM. Acute renal failure with amphotericin B in lipid emulsion [letter]. Ann Pharmacother 1996;30:1036.
31. Devlin J, Bailey E, Zarowitz B, O'Neil MG, Lapointe M, Sorkine P. Administration of amphotericin B in lipid emulsion [letter]. Crit Care Med 1997;25:892-4.
32. Joly V, Geoffray C, Reynes J, et al. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. J Antimicrob Chemother 1996;38:117-26.
33. Joly V, Aubry P, Ndayiragide A, et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996;23:556-62.
34. Petit N, Parola P, Dhiver C, Gastaut JA. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients. J Antimicrob Chemother 1996,38:154-7.
35. Lopez RM, Ayestaran A, Pou L, Montoro JB, Hernandez M, Caragol I. Stability of amphotericin B in an extemporaneously prepared intravenous fat emulsion. Am J Health-Syst Pharm 1996;53:2724-7.
36. Kintzel PE. Amphotericin B in a fat emulsion [letter]. Am J Health-Syst Pharm 1996;53:2701.
37. Heinemann V, Kähny B, Jehn U, et al. Serum pharmacology of amphotericin B applied in lipid emulsions. Antimicrob Agents Chemother 1997;41:728-32.
38. Trissel LA. Amphotericin B does not mix with fat emulsion [letter]. Am J Health-Syst Pharm 1995;52:1463-4.
39. Heide PE. Precipitation of amphotericin B from intravenous fat emulsion [letter]. Am J Health-Syst Pharm 1997;54:1449.
40. Ericsson O, Hallmen AC, Wikstrom I. Amphotericin B is incompatible with lipid emulsions [letter]. Ann Pharmacother 1996;30:298.
41. Ranchére JY, Latour JF, Furhmann C, Lagallarde C, Loreuil F. Amphotericin B lntralipid formulation: stability and particle size. J Antimicrob Chemother 1996;37:1165-9.
42. Montoro JB, Lopez RM, Pou L. Compatibility of amphotericin B with lipid emulsion [letter]. Ann Pharmacother 1996;30:1501.
43. Marzullo L, Souza LC, Campa A. Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes. Gen Pharmacol 1997;28:203-7.